EUVIMEDEUVIMED entdecken
Crossref

Characterization of 12 Unknown Photodegradation Impurities of Tunlametinib Capsules Using Liquid Chromatography Coupled With ion Trap/Time‐Of‐Flight Mass Spectrometry

Ying Yang, Jiarui Gao, Hongxia Zeng iD

Rapid Communications in Mass Spectrometry · 2025

DOI: 10.1002/rcm.10113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rapid Communications in Mass Spectrometry, 2025. Verfasst von Ying Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: China Jiliang University, Hangzhou, China. Hauptthemen laut MEDLINE: Drug Contamination, Mass Spectrometry. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

In March 2024, tunlametinib capsules, a Class 1 new drug (referring to active pharmaceutical ingredients and formulations not previously marketed either nationally or globally), were approved in China for treating patients with advanced melanoma and neuroblastoma RAS viral oncogene homologue mutations who experienced disease progression or intolerance to anti‐PD‐1/PD‐L1 therapy. Risk assessment of impurity profiles is essential for drug safety and efficacy in clinical applications. This study characterized impurity profiles in tunlametinib capsules induced by photodegradation.

Methods

Initial high‐performance liquid chromatography coupled with ion trap/time‐of‐flight mass spectrometry (HPLC/IT‐TOF MS) in positive ion mode was first performed to determine the m / z values of protonated ions and predict the formulas of the detected impurities. Subsequent LC‐MS n analyses ( n = 2–4) of target compounds elucidated comprehensive structural features.

Results

Twelve previously unidentified photodegradation impurities in tunlametinib capsules were characterized using HPLC/IT‐TOF MS.

Conclusions

Structural elucidation of 12 previously uncharacterized photodegradation impurities was achieved through HPLC/IT‐TOF MS. These findings establish a scientific foundation for refining quality specifications of tunlametinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ContaminationMass SpectrometryChromatography, High Pressure LiquidPhotolysisCapsules

Stichwörter der Autor:innen

impurity profileion trap/time‐of‐flight mass spectrometryphotodegradation impuritiestunlametinib capsules

Substanzen

Capsules

Autor:innen und Institutionen

  • China Jiliang University, Hangzhou, China.
  • Zhejiang University of Technology, Hangzhou, China.
  • Key Laboratory for Core Technology of Generic Drug Evaluation National Medical Product Administration, Zhejiang Institute for Food and Drug Control, Hangzhou, China.

ORCID-Profile: Hongxia Zeng

Zitieren

APA

Yang, Y., Gao, J., & Zeng, H. (2025). Characterization of 12 Unknown Photodegradation Impurities of Tunlametinib Capsules Using Liquid Chromatography Coupled With ion Trap/Time‐Of‐Flight Mass Spectrometry. Rapid Communications in Mass Spectrometry. https://doi.org/10.1002/rcm.10113

Vancouver

Yang Y, Gao J, Zeng H. Characterization of 12 Unknown Photodegradation Impurities of Tunlametinib Capsules Using Liquid Chromatography Coupled With ion Trap/Time‐Of‐Flight Mass Spectrometry. Rapid Communications in Mass Spectrometry. 2025. doi:10.1002/rcm.10113

BibTeX
@article{Yang2025,
  author = {Yang, Ying and Gao, Jiarui and Zeng, Hongxia},
  title = {Characterization of 12 Unknown Photodegradation Impurities of Tunlametinib Capsules Using Liquid Chromatography Coupled With ion Trap/Time‐Of‐Flight Mass Spectrometry},
  journal = {Rapid Communications in Mass Spectrometry},
  year = {2025},
  doi = {10.1002/rcm.10113}
}
Kostenlos starten →